全球领先的制药企业诺华（Novartis）和礼来（Eli Lilly）近日与Alphabet旗下的人工智能制药企业Isomorphic Labs达成战略合作，这项价值高达30亿美元的合作预计将推动医药行业的创新进程。
Isomorphic Labs是一家专注于开发基于人工智能技术的小分子药物的初创企业，其独特的AI算法能够快速筛选出具有潜在治疗效果的化合物。此次与诺华和礼来的合作将充分利用Isomorphic Labs的技术优势，加速两家公司的药物研发进程。
据了解，这两项合作均为多靶点合作，旨在寻找并优化一系列小分子化合物，以期发现新的治疗方法。这种新型的合作模式将极大地提高药物研发的效率，降低研发成本，并有可能缩短新药上市的时间。
对于这一合作，Isomorphic Labs的CEO表示：“我们非常高兴能与诺华和礼来这样的行业领导者合作。通过结合我们的AI技术和他们的专业知识，我们将共同推动医药行业的进步。”
随着科技的发展，人工智能在医药领域的应用越来越广泛。诺华、礼来与Isomorphic Labs的战略合作将进一步推动人工智能技术在药物研发中的应用，为全球患者带来更多更好的治疗选择。
英语如下：
News Title: “30 Billion Dollar Deal! Novartis, Eli Lilly Partner with AI Pharma Giant Isomorphic Labs”
Keywords: Novartis, Eli Lilly, AI Pharma
News Content:
Title: Novartis, Eli Lilly and Isomorphic Labs Join Forces to Create a New Era of AI Drug Development
Global leading pharmaceutical companies Novartis (Novartis) and Eli Lilly (Eli Lilly) have recently formed a strategic partnership with Alphabet’s AI pharmaceutical company Isomorphic Labs, a deal valued at an impressive 30 billion dollars. This collaboration is expected to drive innovation in the pharmaceutical industry.
Isomorphic Labs is a startup focused on developing small molecule drugs based on artificial intelligence technology. Their unique AI algorithms can quickly screen out compounds with potential therapeutic effects. The collaboration with Novartis and Eli Lilly will fully leverage Isomorphic Labs’ technological advantages, accelerating the drug development processes of both companies.
It is understood that these two collaborations are multi-target collaborations aimed at discovering and optimizing a series of small molecule compounds in order to discover new treatment methods. This new cooperation mode will greatly improve the efficiency of drug research and development, reduce R&D costs, and potentially shorten the time for new drugs to be launched.
For this collaboration, the CEO of Isomorphic Labs said, “We are very happy to collaborate with industry leaders like Novartis and Eli Lilly. By combining our AI technology with their expertise, we will work together to advance the pharmaceutical industry.”
With the development of technology, the application of artificial intelligence in the pharmaceutical field is becoming more and more extensive. The strategic partnership between Novartis, Eli Lilly and Isomorphic Labs will further promote the application of AI technology in drug development, bringing more and better treatment options to patients around the world.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 1